Lakewood-Amedex Biotherapeutics Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Kelvin Cooper and CFO Peter Ceccacci certified on August 13, 2026 that the Q2 2026 10-Q fairly presents Lakewood-Amedex's financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certifications; no substantive operational, financial, or governance changes disclosed. Boilerplate compliance filing.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.